184 related articles for article (PubMed ID: 30935576)
1. Predictive factors for response and toxicity after brachytherapy for rectal cancer; results from the HERBERT study.
Rijkmans EC; Marijnen CAM; van Triest B; Ketelaars M; Cats A; Inderson A; van den Ende RPJ; Laman MS; Kerkhof EM; Nout RA
Radiother Oncol; 2019 Apr; 133():176-182. PubMed ID: 30935576
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of clinical and endoscopic toxicity after external beam radiotherapy and endorectal brachytherapy in elderly patients with rectal cancer treated in the HERBERT study.
Rijkmans EC; van Triest B; Nout RA; Kerkhof EM; Buijsen J; Rozema T; Franssen JH; Velema LA; Laman MS; Cats A; Marijnen CAM
Radiother Oncol; 2018 Mar; 126(3):417-423. PubMed ID: 29398154
[TBL] [Abstract][Full Text] [Related]
3. Endorectal Brachytherapy Boost After External Beam Radiation Therapy in Elderly or Medically Inoperable Patients With Rectal Cancer: Primary Outcomes of the Phase 1 HERBERT Study.
Rijkmans EC; Cats A; Nout RA; van den Bongard DHJG; Ketelaars M; Buijsen J; Rozema T; Franssen JH; Velema LA; van Triest B; Marijnen CAM
Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):908-917. PubMed ID: 28366579
[TBL] [Abstract][Full Text] [Related]
4. Toxicity outcome of endorectal brachytherapy boost in medically inoperable patients.
Chiang CL; Lee SF; Lee VW; Yeung CS; Cheung SK; Poon MC; Foo DC; Lo SH; Lam KO; Lee FA; Wong FC; Chan MK
Strahlenther Onkol; 2020 Nov; 196(11):993-997. PubMed ID: 32313964
[TBL] [Abstract][Full Text] [Related]
5. Feasibility study of toxicity outcomes using GEC-ESTRO contouring guidelines on CT based instead of MRI-based planning in locally advanced cervical cancer patients.
Koh V; Choo BA; Lee KM; Tan TH; Low JH; Ng SY; Ilancheran A; Shen L; Tang J
Brachytherapy; 2017; 16(1):126-132. PubMed ID: 27816539
[TBL] [Abstract][Full Text] [Related]
6. Late rectal toxicity determined by dose-volume parameters in computed tomography-based brachytherapy for locally advanced cervical cancer.
Zhou YC; Zhao LN; Wang N; Hu J; Sun XH; Zhang Y; Li JP; Li WW; Liu JY; Wei LC; Shi M
Cancer Med; 2016 Mar; 5(3):434-41. PubMed ID: 26806114
[TBL] [Abstract][Full Text] [Related]
7. A systematic review comparing radiation toxicity after various endorectal techniques.
Verrijssen AS; Opbroek T; Bellezzo M; Fonseca GP; Verhaegen F; Gerard JP; Sun Myint A; Van Limbergen EJ; Berbee M
Brachytherapy; 2019; 18(1):71-86.e5. PubMed ID: 30396854
[TBL] [Abstract][Full Text] [Related]
8. Long term experience with 3D image guided brachytherapy and clinical outcome in cervical cancer patients.
Ribeiro I; Janssen H; De Brabandere M; Nulens A; De Bal D; Vergote I; Van Limbergen E
Radiother Oncol; 2016 Sep; 120(3):447-454. PubMed ID: 27157510
[TBL] [Abstract][Full Text] [Related]
9. Predictors of toxicity after image-guided high-dose-rate interstitial brachytherapy for gynecologic cancer.
Lee LJ; Viswanathan AN
Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1192-7. PubMed ID: 22592049
[TBL] [Abstract][Full Text] [Related]
10. Dosimetric factors predicting severe radiation-induced bowel complications in patients with cervical cancer: combined effect of external parametrial dose and cumulative rectal dose.
Huang EY; Wang CJ; Hsu HC; Hao Lin ; Chen HC; Sun LM
Gynecol Oncol; 2004 Oct; 95(1):101-8. PubMed ID: 15385117
[TBL] [Abstract][Full Text] [Related]
11. High-dose-rate brachytherapy boost for prostate cancer: Analysis of dose-volume histogram parameters for predicting late rectal toxicity.
Chicas-Sett R; Farga D; Perez-Calatayud MJ; Celada F; Roldan S; Fornes-Ferrer V; Ibanez-Rosello B; Tormo A; Benlloch JM; Perez-Calatayud J
Brachytherapy; 2017; 16(3):511-517. PubMed ID: 28366276
[TBL] [Abstract][Full Text] [Related]
12. Intermediate dose-volume parameters and the development of late rectal toxicity after MRI-guided brachytherapy for locally advanced cervix cancer.
Ujaimi R; Milosevic M; Fyles A; Beiki-Ardakani A; Carlone M; Jiang H; Lindsay P; Xie J; Gerber R; Croke J; Skliarenko J; Levin W; Han K
Brachytherapy; 2017; 16(5):968-975.e2. PubMed ID: 28757404
[TBL] [Abstract][Full Text] [Related]
13. Dynamics of High Risk Clinical Target Volume reduction during Brachytherapy and impact on its coverage in patients with inoperable cervical cancer.
Pobijakova M; Scepanovic D; Paluga M; Fekete M; Mardiak J
Neoplasma; 2018 Mar; 65(3):425-430. PubMed ID: 29788726
[TBL] [Abstract][Full Text] [Related]
14. Correlation between dosimetric parameters and late rectal and urinary toxicities in patients treated with high-dose-rate brachytherapy used as monotherapy for prostate cancer.
Konishi K; Yoshioka Y; Isohashi F; Sumida I; Kawaguchi Y; Kotsuma T; Adachi K; Morimoto M; Fukuda S; Inoue T
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1003-7. PubMed ID: 19345517
[TBL] [Abstract][Full Text] [Related]
15. Image-guided high-dose-rate brachytherapy for rectal cancer: technical note and first clinical experience on an organ-preserving approach.
Fleischmann M; Diefenhardt M; Trommel M; Scherf C; Ramm U; Chatzikonstantinou G; Fokas E; Rödel C; Tselis N
Strahlenther Onkol; 2022 Jul; 198(7):654-662. PubMed ID: 35445815
[TBL] [Abstract][Full Text] [Related]
16. Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis.
Snyder KM; Stock RG; Hong SM; Lo YC; Stone NN
Int J Radiat Oncol Biol Phys; 2001 Jun; 50(2):335-41. PubMed ID: 11380219
[TBL] [Abstract][Full Text] [Related]
17. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
18. Predictive factors of long-term rectal toxicity following permanent iodine-125 prostate brachytherapy with or without supplemental external beam radiation therapy in 2216 patients.
Tanaka T; Yorozu A; Sutani S; Yagi Y; Nishiyama T; Shiraishi Y; Ohashi T; Hanada T; Saito S; Toya K; Shigematsu N
Brachytherapy; 2018; 17(5):799-807. PubMed ID: 29936128
[TBL] [Abstract][Full Text] [Related]
19. Conformal preoperative endorectal brachytherapy treatment for locally advanced rectal cancer: early results of a phase I/II study.
Vuong T; Belliveau PJ; Michel RP; Moftah BA; Parent J; Trudel JL; Reinhold C; Souhami L
Dis Colon Rectum; 2002 Nov; 45(11):1486-93; discussion 1493-5. PubMed ID: 12432296
[TBL] [Abstract][Full Text] [Related]
20. Late rectal toxicity after low-dose-rate brachytherapy: incidence, predictors, and management of side effects.
Kishan AU; Kupelian PA
Brachytherapy; 2015; 14(2):148-59. PubMed ID: 25516492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
